睫状体光凝术治疗玻璃体切割术后继发青光眼的疗效

目的：评估睫状体光凝术治疗玻璃体切割术后(水眼)继发青光眼的安全性和有效性。

方法：回顾性分析我院2014-10/2016-10收治的玻璃体切割术后(水眼)继发青光眼患者20例20眼的临床资料，对所有患者进行经巩膜睫状体光凝术，术后持续随访3mo，观察术后视力、眼压和并发症情况。

结果：术后1mo时，9眼眼压控制不佳，4眼再次行睫状体光凝术后3眼眼压降至正常。末次随访时，视力较术前差异无统计学意义(P=0.655)； 14眼(70%)患者眼压得到有效控制，眼压(24.6±11.4mmHg)较术前(42.3±5.9mmHg)改善，差异有统计学意义(P<0.05)。术后未出现眼球萎缩、脉络膜上腔出血等严重并发症。

结论：睫状体光凝术对玻璃体切割术后(水眼)继发青光眼患者是一种安全有效、可重复的手术方式。

Observation of transscleral cyclophotocoagulation for glaucoma secondary to vitrectomy

AIM: To evaluate the clinical efficacy and safety of transscleral cyclophotocoagulation(TSCP)for glaucoma secondary to vitrectomy.

METHODS: A retrospective review was performed within 20 patients(20 eyes)with glaucoma secondary to vitrectomy underwent TSCP in our hospital from October 2014 to October 2016. The follow-up time was 3mo. The postoperative visual acuity, intraocular pressure(IOP)and complications were observed.

RESULTS: One month after operation, the postoperative IOP increased in 9 cases. Another 4 eyes were performed TSCP again, and three of them got the normal IOP recovery. At the last follow-up, visual acuity had no significant changes(P=0.655); IOP was effectively controlled in 14(70%)patients. Meanwhile, the mean postoperative IOP(24.6±11.4mmHg)was statistically reduced than the mean preoperative IOP(42.3±5.9mmHg, P<0.05). No serious complications, like hypotony and suprachoroidal hemorrhage, had been observed during 3-month follow-up.

CONCLUSION: TSCP procedure is a safe, effective, repeatable surgery for patients with glaucoma secondary to vitrectomy.